Core Viewpoint - Avalon GloboCare Corp. has entered into a memorandum of understanding with Qi Diagnostics to explore a strategic collaboration for developing a VOC nanosensor-based cannabis breathalyzer, with an exclusivity period of 120 days for negotiations [1][2][3] Group 1: Collaboration Details - The proposed collaboration will focus on the initial prototype-enabling stage, involving critical research, data collection, software development, and prototype design for the cannabis breathalyzer [2] - Avalon believes its regulatory expertise will be beneficial in navigating the regulatory pathways, clinical trials, and approval processes in the United States [2][3] Group 2: Company Background - Avalon GloboCare Corp. is dedicated to developing innovative precision diagnostics and clinical laboratory services, aiming to establish a leading role in diagnostic testing innovation [4] - The company offers a broad portfolio of diagnostic tests, including drug testing, toxicology, general bloodwork, anatomic pathology, and urine toxicology [4]
Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving